Just one dose of human papillomavirus (HPV) vaccine has similar effectiveness to two or three doses for preventing cervical pre-cancer, according to a new study.
In a comprehensive public knowledge linkage study published in Papillomavirus Research, researchers compared cervical screening outcomes for a quarter of a million Australian women who had been eligible for vaccination under the national program.
Researchers discovered that in ladies who had been vaccinated at a younger age, when most had not but been uncovered to HPV, that receipt of even one dose of HPV vaccine lowered the prospect of getting a pre-cancerous lesion detected at cervical screening.
Lead author, Julia Brotherton from the VCS Foundation and the University of Melbourne, mentioned this data adds to contrary evidence starting to emerge that one dose of HPV vaccine may ultimately prove to be enough for protection.
Vaccination is a key a part of the World Health Organisation’s recent call to work in the direction of the elimination of cervical cancer as a public health downside, along with HPV based screening, facilities for early diagnosis and treatment, and palliative care.
In Australia, HPV vaccination is routinely supplied free of charge under the National Immunisation Program to both girls and boys in early high school at age 12-13 years, with free catch up available up to the age of 19 through local doctors and clinics.
Recent data from Denmark and the US additionally help the chance that one dose may be ample. However, outcomes of randomized trials are anticipated before official recommendations are changed.
The data was investigated by a team of researchers from the VCS Foundation, the Australian Institute of Health and Welfare and cervical screening program managers from the ACT, NT, Tasmania, Victoria, and Western Australia.